Heidelberg Pharma AG (HPHA):企業の財務・戦略的SWOT分析

◆英語タイトル:Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH123319FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年1月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Heidelberg Pharma AG (HPHA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Heidelberg Pharma AG (Heidelberg Pharma) is a biopharmaceutical company that develops novel therapeutics for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, non-hodgkin lymphoma, blood cancers, generic diseases and solid tumors. Through its subsidiary Heidelberg Pharma Research GmbH provides preclinical contract research services and is the first company to develop the toxin Amanitin into oncology therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.

Heidelberg Pharma AG Key Recent Developments

Oct 22,2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services
Oct 08,2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020
Sep 14,2020: Heidelberg Pharma receives milestone payment from Partner Magenta
Jul 09,2020: Heidelberg Pharma reports on first half-year 2020
Apr 23,2020: Heidelberg Pharma: Interim management statement on the first three months of 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Heidelberg Pharma AG – Key Facts
Heidelberg Pharma AG – Key Employees
Heidelberg Pharma AG – Key Employee Biographies
Heidelberg Pharma AG – Major Products and Services
Heidelberg Pharma AG – History
Heidelberg Pharma AG – Company Statement
Heidelberg Pharma AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Heidelberg Pharma AG – Business Description
Business Segment: ADC Technology Sales Revenue
Performance
Business Segment: Out-licensing Sales Revenue
Performance
Business Segment: Service Business Sales Revenue
Capital Expenditure
Geographical Segment: Europe
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: The US
Performance
Heidelberg Pharma AG – Corporate Strategy
Heidelberg Pharma AG – SWOT Analysis
SWOT Analysis – Overview
Heidelberg Pharma AG – Strengths
Heidelberg Pharma AG – Weaknesses
Heidelberg Pharma AG – Opportunities
Heidelberg Pharma AG – Threats
Heidelberg Pharma AG – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heidelberg Pharma AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 22, 2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services
Oct 08, 2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020
Sep 14, 2020: Heidelberg Pharma receives milestone payment from Partner Magenta
Jul 09, 2020: Heidelberg Pharma reports on first half-year 2020
Apr 23, 2020: Heidelberg Pharma: Interim management statement on the first three months of 2020
Mar 19, 2020: Heidelberg Pharma announces financial figures for fiscal year 2019 and provides business update
Mar 04, 2020: Heidelberg Pharma: US patent rights granted for diagnosis and treatment of patients with TP53/RNA polymerase II deletion
Jan 22, 2020: Heidelberg Pharma secures financing commitment from its main shareholder dievini
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Heidelberg Pharma AG, Key Facts
Heidelberg Pharma AG, Key Employees
Heidelberg Pharma AG, Key Employee Biographies
Heidelberg Pharma AG, Major Products and Services
Heidelberg Pharma AG, History
Heidelberg Pharma AG, Subsidiaries
Heidelberg Pharma AG, Key Competitors
Heidelberg Pharma AG, Ratios based on current share price
Heidelberg Pharma AG, Annual Ratios
Heidelberg Pharma AG, Annual Ratios (Cont...1)
Heidelberg Pharma AG, Interim Ratios
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heidelberg Pharma AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Heidelberg Pharma AG (HPHA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Steris Corp-医療機器分野:企業M&A・提携分析
    Summary Steris Corp (Steris), formerly Innovative Medical Technologies, a subsidiary of Steris Plc, is a medical device company that offers infection prevention and other procedural products and services. The company offers surgical equipment and image management, sterile processing equipment, surgi …
  • Zecotek Photonics Inc (ZMS):企業の財務・戦略的SWOT分析
    Zecotek Photonics Inc (ZMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Mediq NV:企業の戦略的SWOT分析
    Mediq NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • TesoRx Pharma LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary TesoRx Pharma LLC (TesoRx) is a pharmaceutical company that develops treatments to address unmet medical needs. The company’s product pipeline comprises TSD-001, TSD-005, TSX-011 and TSX-002. Its TSD-001is an intravesical paclitaxel for the treatment of non-muscle invasive bladder cancer. Te …
  • Stellar Biotechnologies Inc (SBOT):医療機器:M&Aディール及び事業提携情報
    Summary Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injecta …
  • Jardine Matheson Holdings Limited:戦略・SWOT・企業財務分析
    Jardine Matheson Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Matheson Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Space Exploration Technologies Corp:企業の戦略・SWOT・財務情報
    Space Exploration Technologies Corp - Strategy, SWOT and Corporate Finance Report Summary Space Exploration Technologies Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Gammon Infrastructure Projects Ltd (GAMMNINFRA):企業の財務・戦略的SWOT分析
    Gammon Infrastructure Projects Ltd (GAMMNINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Westdeutsche Immobilien Servicing AG:企業の戦略・SWOT・財務分析
    Westdeutsche Immobilien Servicing AG - Strategy, SWOT and Corporate Finance Report Summary Westdeutsche Immobilien Servicing AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Eversource Energy (ES):電力:M&Aディール及び事業提携情報
    Summary Eversource Energy (Eversource) is a utility holding company, which operates energy delivery business through its subsidiaries. It transmits and distributes electricity and natural gas. The company sources electricity from its facilities, long-term power supply agreements, and competitive ene …
  • Organo Corporation:企業の戦略・SWOT・財務情報
    Organo Corporation - Strategy, SWOT and Corporate Finance Report Summary Organo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PT. Bank Rakyat Indonesia (Persero) Tbk.:企業の戦略・SWOT・財務情報
    PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Gadeta BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Gadeta BV (Gadeta) is a biotechnology company, which focuses on the research and development of cellular immunotherapies for the elimination of cancer. The company’s technology platform combines alpha beta T cells engineered to express defined Gamma Delta T cell receptors (TEGs) that demonst …
  • Herman Miller, Inc.:企業の戦略・SWOT・財務情報
    Herman Miller, Inc. - Strategy, SWOT and Corporate Finance Report Summary Herman Miller, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Celyad SA (CYAD):企業の財務・戦略的SWOT分析
    Summary Celyad SA (Celyad), formerly Cardio3 BioSciences, is a clinical-stage biopharmaceutical company that offers discovery and development of engineered cell therapies. The company offers C-Cure, a cell-based reparative therapy to treat heart failure. It offers C-Cathez, an intraventricular injec …
  • Xped Ltd (XPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Xped Ltd (Xped) formerly Raya Group Limited, is an Internet of Things company that develops software and hardware solutions. It offers auto discovery remote control, Xerts, and Xped app software; and hardware such as Xped ADRC Shields, Umbo-Xped ADRC Hub, UltraPlug, VariPlug, IRBlaster. The …
  • United States Lime & Minerals Inc:企業の戦略・SWOT・財務分析
    United States Lime & Minerals Inc - Strategy, SWOT and Corporate Finance Report Summary United States Lime & Minerals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Sojitz Corporation (2768)-エネルギー分野:企業M&A・提携分析
    Summary Sojitz Corporation (Sojitz) is a diversified general trading group. The group through its subsidiaries and affiliates holds interest in machinery; energy and metals; chemicals and functional materials; and consumer lifestyle businesses. It distributes automobiles and aircraft; develops power …
  • Nippon Sheet Glass Company Limited :企業の戦略・SWOT・財務情報
    Nippon Sheet Glass Company Limited - Strategy, SWOT and Corporate Finance Report Summary Nippon Sheet Glass Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • NABsys Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary NABsys Inc (NABsys) is a biomedical service provider. The company designs and develops semiconductor-based tools for genomic analysis. It develops semiconductor based nanodetectors to analyze DNA molecules electronically. NABsys provides platform to detect the positions of hybridized DNA pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆